SCHEMBL1375792

SCHEMBL1375792

COc1ccc(S(=O)(=O)n2cc(-c3ccc(N)nc3)cc2-c2cc(OC)c(OC)c(OC)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FYN P06241 4/20 0.46
ABL1 P00519 1/20 0.43
FLT3 P36888 1/20 0.43
MAPT P10636 4/20 0.41
LMNA P02545 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAP3K11 Q16584 1/20 0.41
LRRK2 Q5S007 1/20 0.41
POLB P06746 1/20 0.41
BRD4 O60885 1/20 0.39
ALPL P05186 1/20 0.39
EPHB4 P54760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379286 0.86 ALDH1A1 (0.45) FYNMAPTLMNACA1CA2
SCHEMBL1375760 0.83 CYP11B2 (0.48) KMT2APOLBALPL
SCHEMBL1378956 0.79 CYP11B1 (0.47) FYNMAPTLMNAMAP3K11ALPL
SCHEMBL3371555 0.77 CA12 (0.43) MAPTLMNACA1CA2CA12
SCHEMBL1376420 0.76 CA2 (0.61) MAPTLMNACA1CA2CA12
SCHEMBL3369368 0.76 TUBB1 (0.44) MAPTLMNACA1CA2CA12
SCHEMBL5696246 0.75 L3MBTL1 (0.47) CA1CA2CA12CA9KMT2A
SCHEMBL20589457 0.73 ABL1 (0.64) FYNABL1FLT3MAP3K11LRRK2
SCHEMBL1379606 0.73 MAP3K11 (0.48) FYNCA1CA2CA12CA9
SCHEMBL5696178 0.72 RAPGEF4 (0.53) MAPTCA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4716996-B2 2011-07-06 JP claimed
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 EP claimed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US claimed
EP-1628957-A1 SULFOPYRROLES Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP claimed
WO-2004103968-A1 SULFOPYRROLES APONETICS AG (CH) 2004-12-02 WO claimed
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 EP disclosed
US-7612064-B2 Sulfopyrroles TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-03 US disclosed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US disclosed
EP-1628957-A1 SULFOPYRROLES Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP disclosed
WO-2004103968-A1 SULFOPYRROLES APONETICS AG (CH) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060570-A1 Sulfopyrroles TYK2, ARSA, SULT2A1 FYN 120/4885ABL1 23/4885FLT3 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.